Literature DB >> 27796718

Continuous positive airway pressure usage in hospitalized patients with known obstructive sleep apnea: discrepancy between admission pressure settings and laboratory-determined settings.

Parmeet Saini1, Emile Klada1, Vishal Patel1, Moe Zaw1, Boris Dubrovsky1, Liziamma George1, Elizabeth M Bachman1, Jeremy A Weingarten2.   

Abstract

PURPOSE: The aim of this study was to determine the frequency and predictors of correctly initiated continuous positive airway pressure (CPAP) settings on the initial night of hospitalization in patients with known obstructive sleep apnea-hypopnea syndrome (OSAHS).
METHODS: Hospital records of all patients who underwent an outpatient therapeutic polysomnogram (PSG) at our institution between January 2005 and December 2010 were retrospectively reviewed. Data collected included initial CPAP settings on hospital admission, latency to hospitalization (from sleep study), hospital length of stay, demographic variables, and PSG variables.
RESULTS: One hundred seventy subjects were included in the analysis: 51 % were male, average age (±SD) was 55.3 ± 13.7 years, and body mass index was 43.7 ± 10.4 kg/m2. OSAHS was generally severe (apnea-hypopnea index (AHI) 52.8 ± 37.3 event/h). Mean CPAP setting during in-laboratory titration was 11.1 ± 3.1 cm H2O and during the first night of hospitalization was 9.5 ± 2.8 cm H2O (p < 0.0001). Of 170 subjects, only 71 (42 %) received the correct laboratory-derived CPAP setting on the first night of hospitalization. In a multivariable logistic regression analysis, higher body mass index (BMI), lower CPAP level determined during PSG, and shorter latency (months) between PSG and hospitalization were associated with receiving the correct CPAP setting during the first night of hospitalization: Each 1 kg/m2 increase in BMI was associated with a 7 % increase odds of receiving the correct CPAP setting during the first night of hospitalization (OR 1.07, 95 % CI 1.02-1.12), while each 1 cm H2O increase in CPAP during PSG and each 1 month longer latency between PSG and hospitalization was associated with a 15 and 7 %, respectively, decrease in the odds of receiving the correct CPAP setting during the first night of hospitalization (CPAP OR 0.85, 95 % CI 0.74-0.97 and latency OR 0.93, 95 % CI 0.90-0.97). There was no in-hospital mortality, and correct CPAP settings did not affect hospital length of stay.
CONCLUSIONS: Among patients admitted to the hospital, a correct, laboratory-derived CPAP setting is infrequently prescribed during the first night of hospitalization. Predictors for correctly ordering CPAP include latency from the time of in-laboratory CPAP titration, BMI, and laboratory-derived CPAP level.

Entities:  

Keywords:  Continuous positive airway pressure; Hospitalization; Obstructive sleep apnea

Mesh:

Year:  2016        PMID: 27796718     DOI: 10.1007/s11325-016-1420-2

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  17 in total

1.  Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial.

Authors:  Malcolm Kohler; Anne-Christin Stoewhas; Lisa Ayers; Oliver Senn; Konrad E Bloch; Erich W Russi; John R Stradling
Journal:  Am J Respir Crit Care Med       Date:  2011-11-15       Impact factor: 21.405

2.  Elevated levels of endothelial cell-derived microparticles following short-term withdrawal of continuous positive airway pressure in patients with obstructive sleep apnea: data from a randomized controlled trial.

Authors:  Lisa Ayers; Anne-Christin Stoewhas; Berne Ferry; John Stradling; Malcolm Kohler
Journal:  Respiration       Date:  2012-11-13       Impact factor: 3.580

3.  Health care utilization in the 10 years prior to diagnosis in obstructive sleep apnea syndrome patients.

Authors:  J Ronald; K Delaive; L Roos; J Manfreda; A Bahammam; M H Kryger
Journal:  Sleep       Date:  1999-03-15       Impact factor: 5.849

4.  Association between treated and untreated obstructive sleep apnea and risk of hypertension.

Authors:  José M Marin; Alvar Agusti; Isabel Villar; Marta Forner; David Nieto; Santiago J Carrizo; Ferran Barbé; Eugenio Vicente; Ying Wei; F Javier Nieto; Sanja Jelic
Journal:  JAMA       Date:  2012-05-23       Impact factor: 56.272

5.  Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study.

Authors:  R M Gupta; J Parvizi; A D Hanssen; P C Gay
Journal:  Mayo Clin Proc       Date:  2001-09       Impact factor: 7.616

6.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares.

Authors:  C E Sullivan; F G Issa; M Berthon-Jones; L Eves
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

8.  Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults.

Authors:  Lawrence J Epstein; David Kristo; Patrick J Strollo; Norman Friedman; Atul Malhotra; Susheel P Patil; Kannan Ramar; Robert Rogers; Richard J Schwab; Edward M Weaver; Michael D Weinstein
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

9.  Prevalence of unspecified sleep apnea and the use of continuous positive airway pressure in hospitalized patients, 2004 National Hospital Discharge Survey.

Authors:  Kathy F Spurr; Michael A Graven; Robert W Gilbert
Journal:  Sleep Breath       Date:  2008-01-31       Impact factor: 2.816

10.  Prevalence and associated factors of obstructive sleep apnea in hospitalized patients with type 2 diabetes in Beijing, China 2.

Authors:  Rui Zhang; Xiaohui Guo; Lixin Guo; Juming Lu; Xianghai Zhou; Linong Ji
Journal:  J Diabetes       Date:  2014-09-06       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.